HIV AIDS Congress 2019 invites all intended participants to attend "2nd World Congress on HIV AIDS STD and STI" scheduled on September 09-10 at Bangkok, Thailand. HIV AIDS Congress 2019 is a unique and open platform to discover and gain the knowledge in the field of Life Science. The conference brings together Professors, Researchers, Scientists, Practitioners, Health Care Experts, Public Health Professionals and Students from all the zones of Medical Sciences. It will offer an exciting Scientific Program, composed of Plenary Lectures, Poster Presentation, Workshops and Abstract-driven sessions presenting the latest research in the field of HIV/AIDS. Furthermore, HIV AIDS Congress 2019 conference will also provide an opportunity for younger investigators to participate actively and present their research.
Sexually transmitted diseases cause genuine wellbeing confusions, for example, barrenness in the two people, ectopic pregnancy, pelvic fiery infection, stillbirth, neurologic harm, tumor and high grimness in grown-ups. There are around 20 million new STD contaminations every year. According to WHO report in 2015, around 1.1 billion individuals had explicitly transmitted infections other than HIV/AIDS. Around 500 million individuals were contaminated with either chlamydia, gonorrhea, syphilis or trichomoniasis. No less than 250 million ladies experiencing human papillomavirus while 530 million case find with genital herpes. Doctors and social insurance suppliers assume a key job in counteractive action and treatment of STDs. The overall STD indicative market was esteemed at over USD 100.0 billion of every 2014. The progressions in STD indicative innovations offers more exact test outcomes which adds to the ascent in the market estimation of STD diagnostics industry. Low intentional screening rate for explicitly transmitted infections is a noteworthy control for this market. Sexually transmitted diseases demonstrative market was USD 103.20 billion of every 2015 and is required to stretch around USD 166.50 by 2021, developing at a CAGR of around 8.3% somewhere in the range of 2015 and 2021.
Explicitly transmitted sicknesses are a worldwide level medical problem with continuous innovative Among different treatments, the by and large utilized present day treatment for STDs are anti-infection agents. The worldwide STD sedate market is relied upon to indicate consistent development because of the high pervasiveness of explicitly transmitted malady as of late. The high wellbeing hazard related with the ailment builds the requirement for analysis, aversion and treatment for the explicitly transmitted infections. The patient's readiness to pick propelled treatment will support the worldwide medication advertise estimation of the explicitly transmitted maladies. Change in the human services worldwide and rising per capita pay are the significant segments which drives the social insurance change supporting STD analytic industry development. HPV diseases comprise 5,00,000 cases/year of which 80% are purportedly from creating nations. The ascent in occurrence of different contaminations, for example, syphilis, chlamydia, gonorrhea, human papillomavirus, herpes simplex infection, chancroid and trichomoniasis is required to build the interest for medications all inclusive. Organizations assuming significant job in the worldwide explicitly transmitted infections sedate market are Pfizer INC, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson and Johnson, Bristol-Myers Squibb Co. AbbVie, Inc., Gilead Sciences, GlaxoSmithKline Plc, and Merck and Co., Inc.
According to Global Data, Sexually Transmitted Disease Market is expected to grow at a CAGR of 8.7% through the forecast period (2017–2022). A group of illnesses that can be transmitted from one person to another through the sharing of body fluids, vaginal fluids and blood is known as STD (Sexually Transmitted Diseases). Technavio's analysts forecast the global sexually transmitted disease testing market to grow at a CAGR of 5.64% over the period 2013-2017. The global STD diagnostics market added up for almost USD 103.20 Billion in 2017 and is likely to cross almost USD 166.50 by end of 2022, developing at a CAGR of almost 8.7% from 2017 to 2022.
Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022. In 2017 the global HIV drugs market exceeded a value of US$ 17 Billion. Looking forward, the market value is expected to reach nearly US$ 21 Billion by 2023, expanding at a CAGR of more than 3% during 2018-2023.
The ratio between deaths and individuals living with HIV in the year 2017 is 56% were accessing treatment. Out of those, 47% were virally suppressed. Tuberculosis (TB) remains the primary cause of death among people living with HIV. In 2017, 0.9 million individuals died from AIDS-related illnesses worldwide, compared to 1.9 million in 2004 and 1.4 million in 2010. AIDS-related deaths have been decreased by more than 51% since the peak in 2004.
Since the beginning of the HIV epidemic, more than 70 million individuals were infected approximately with the HIV virus and about 35 million people died of HIV. Universally, 36.9 million [31.1–43.9 million] people are living with HIV at the end of 2017. An expected 0.8% [0.6-0.9%] of adults aged 15–49 years affected with HIV, although the burden of the epidemic continues to vary considerably between countries and regions. The WHO African region remains most severely affected, with nearly 1 in every 25 adults (4.1%) living with HIV and accounting for nearly two-thirds of the people living with HIV worldwide.